Treats hypertension. ANDA 74910, held by Mylan. Diltiazem Hydrochloride.
As of Nov 16, 2026, ANDA 74910 (Diltiazem Hydrochloride), held by Mylan, was first approved by FDA on May 2, 1997, with 4 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Diltiazem hydrochloride extended-release capsules (Twice-a-Day Dosage) are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive medications, such as diuretics.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 2, 1997 | Original application | Approved |
| Diltiazem Hydrochloride60MG · capsule, extended release;oral | Diltiazem Hydrochloride | Rx |
| Diltiazem Hydrochloride90MG · capsule, extended release;oral | Diltiazem Hydrochloride | Rx |
| Diltiazem Hydrochloride120MG · capsule, extended release;oral | Diltiazem Hydrochloride | Rx |
| May 6, 2025 | Supplement 28Labeling · Standard review | Approved | None posted |
| Sep 12, 2024 | Supplement 19Labeling · Standard review | Approved | None posted |
| Oct 11, 2002 | Supplement 2Manufacturing | Approved | None posted |
| Nov 27, 2000 | Supplement 1Labeling | Approved | None posted |
| May 2, 1997 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters